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The tamoxifen-inducible Cre-loxP system is widely used to overcome gene targeting
pre-adult lethality, to modify a specific cell population at desired time-points, and to
visualize and trace cells in fate-mapping studies. In this study we focused on tamoxifen
degradation kinetics, because for all genetic fate-mapping studies, the period during
which tamoxifen or its metabolites remain active in the CNS, is essential. Additionally,
we aimed to define the tamoxifen administration scheme, enabling the maximal
recombination rate together with minimal animal mortality. The time window between
tamoxifen injection and the beginning of experiments should be large enough to allow
complete degradation of tamoxifen and its metabolites. Otherwise, these substances
could promote an undesired recombination, leading to data misinterpretation. We
defined the optimal time window, allowing the complete degradation of tamoxifen
and its metabolites, such as 4-hydroxytamoxifen, N-desmethyltamoxifen, endoxifen
and norendoxifen, in the mouse brain after intraperitoneal tamoxifen injection. We
determined the biological activity of these substances in vitro, as well as a minimal
effective concentration of the most potent metabolite 4-hydroxytamoxifen causing
recombination in vivo. For this purpose, we analyzed the recombination rate in double
transgenic Cspg4-cre/Esr1/ROSA26Sortm14(CAG-tdTomato) mice, in which tamoxifen
administration triggers the expression of red fluorescent protein in NG2-expressing
cells, and employed a liquid chromatography, coupled with mass spectrometry, to
determine the concentration of studied substances in the brain. We determined
the degradation kinetics of these substances, and revealed that this process is
influenced by mouse strains, age of animals, and dosage. Our results revealed that
tamoxifen and its metabolites were completely degraded within 8 days in young
adult C57BL/6J mice, while the age-matched FVB/NJ male mice displayed more
effective degradation. Moreover, aged C57BL/6J mice were unable to metabolize
all substances within 8 days. The lowering of initial tamoxifen dose leads to a
significantly faster degradation of all studied substances. A disruption of the blood-brain
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barrier caused no concentration changes of any tamoxifen metabolites in the ipsilateral
hemisphere. Taken together, we showed that tamoxifen metabolism in mouse brains is
age-, strain- and dose-dependent, and these factors should be taken into account in
the experimental design.
Keywords: tamoxifen, brain metabolism, fate-mapping, Cre-loxP, gene-targeting
INTRODUCTION
Gene targeting has proven to be a powerful tool for precise
manipulation of the mammalian genome, by generating
thousands of mutant mouse strains. Studies of these mutant
mice have yielded extremely useful information in all fields
of biological sciences, and theoretically, gene targeting can be
used to generate mutant mice for all genes in the near future.
However, many genes are essential for development and their
mutations result in pre-adult lethality, preventing further
studies of their functions in adulthood (Weinstein et al., 2000;
Deng, 2002; Coumoul and Deng, 2003; Friedberg and Meira,
2006). In the past decades, Cre-loxP technology, combined
with tamoxifen-inducible systems, has been used to overcome
this pre-adult lethality (Le and Sauer, 2000). In addition, this
technology has enabled precise gene manipulation in distinct
cell subpopulations at any specific time point, which is known
as temporally and spatially controllable gene expression. Besides
gene knockout, Cre-loxP technology has enabled labeling
of any cell types, and following their fate, which is called
genetic fate-mapping technique. The main inducer of these
genetic modifications is tamoxifen, which enables enzymatic
activity of Cre-mutated estrogen receptor (Cre-ERTM) fusion
protein, and therefore knowledge of tamoxifen administration,
metabolism and degradation in a living organism is of great
importance. There exist several ways of tamoxifen administration
(orally, intraperitoneally, and in drinking water) with different
advantages and disadvantages, and simultaneously, fundamental
ways of metabolism and degradation of tamoxifen and its
metabolites are already known. Despite the fact that a great part
of all genes are expressed in the central nervous system (CNS)
and numerous genetic modifications target various cells in the
nervous tissue, only a limited amount of information regarding
tamoxifen metabolism in this organ is available. Since many
processes taking place in the CNS show different properties when
compared to the rest of the organism (e.g., due to the presence of
the blood-brain barrier, high vascularization, immune privileged
tissue, different enzymes etc.) tamoxifen metabolism could
also be different, and therefore, the tamoxifen-dependent
recombination rate could be altered when compared to in vitro
conditions or other organs.
In the present study, we analyzed the degradation kinetics
of tamoxifen and its metabolites in mouse brains after
intraperitoneal administration, and we focused on the variances
among mice of different age, sex or strain background.
Simultaneously, we also examined different application schemes
and doses of tamoxifen. The aim of this study is to define the
tamoxifen administration scheme, which will enable the maximal
recombination level together with minimal animal mortality.
Additionally, we also focused on tamoxifen degradation kinetics,
because for all genetic fate-mapping studies, the period during
which tamoxifen or its metabolites remain active in the CNS, is
essential.
MATERIALS AND METHODS
Animals
All procedures involving the use of laboratory animals were
performed in accordance with the European Communities
Council Directive, 24 November 1986 (86/609/EEC) and animal
care guidelines approved by the Institute of Experimental
Medicine, Academy of Sciences of the Czech Republic (Animal
Care Committee on April 7, 2011; approval number 018/2011).
All efforts were made to minimize both the suffering and the
number of animals used. Experiments were performed on
young adult (60–90 days) or aged (over 15 months) C57BL/6J
and FVB/NJ mice. For the purpose of cell quantification we
used transgenic mice, which were derived by crossing the
mouse strain B6.Cg-Tg(Cspg4-cre-Esr1∗)BAkik/J and B6;129S6-
Gt(ROSA)26Sortm14 (CAG-tdTomato)Hze/J (further termed
Cspg4/Tomato mouse), (Jackson Laboratory, Bar Harbor, ME,
USA), in which the expression of tamoxifen-inducible Cre
recombinase is controlled by the Cspg4 promoter (Zhu et al.,
2011). After tamoxifen/4-hydroxytamoxifen administration,
tomato red fluorescent protein is expressed in Cspg4-positive
cells – predominantly in NG2 glia and cells derived therefrom,
e.g., differentiating oligodendrocytes and moreover in a small
subpopulation of pericytes (Supplemental Figure S1A).
Tamoxifen and Its Derivatives Solutions
For all in vitro experiments the tamoxifen and its derivatives
were dissolved in ethanol (96%, Sigma–Aldrich, St. Louis, MO,
USA). For in vivo experiments we used tamoxifen (20 mg/ml,
Toronto Research Chemicals INC, Toronto, ON, Canada)
dissolved in corn oil (Sigma–Aldrich, St. Louis, MO, USA) or
4-hydroxytamoxifen (20 mg/ml, Toronto Research Chemicals
INC, Toronto, ON, Canada) dissolved in ethanol (96%, Sigma–
Aldrich, St. Louis, MO, USA) and further diluted in corn oil to
desired concentration.
Induction of Focal Cerebral Ischemia in
Young Adult Mice
Prior to the induction of focal cerebral ischemia (FCI), the
young adult mice were anesthetized with 3% isoflurane (Abbot,
Abbott Park, IL, USA) and maintained in 2% isoflurane using a
vaporizer (Tec-3, Cyprane Ltd, Keighley, UK). A skin incision
between the orbit and the external auditory meatus was made,
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and a 1–2 mm hole was drilled through the frontal bone, 1 mm
rostrally to the fusion of the zygoma and the squamosal bone,
and about 3.5 mm ventrally to the dorsal surface of the brain.
The middle cerebral artery (MCA) was exposed after the dura
was opened and removed. The MCA was occluded by short
coagulation with bipolar tweezers (SMT, Czech Republic), at a
proximal location, followed by transection of the vessel to ensure
permanent occlusion. During the surgery, body temperature was
maintained at 37± 1◦C using a heating pad. This MCA occlusion
(MCAo) model yields small infarct lesions in the parietal cortical
region (Honsa et al., 2013).
Preparation of Tomato-Positive Cell
Cultures from the Neonatal Mouse Brain
Neonatal 0–3 days old Cspg4/Tomato mice were decapitated,
whole brains were dissected out and mechanically dissociated
by gentle trituration using 1 ml pipette in DMEM/F12 medium,
with penicillin/streptomycin (all from Invitrogen, Carlsbad,
CA, USA), 20 ng/ml PDGFα (Peprotech, Rocky Hill, NJ, USA),
4 mM glutamine (Sigma–Aldrich, St. Louis, MO, USA) and
15% fetal bovine serum (HyClone, Thermo Scientific, Waltham,
MA, USA), further referred to as basal medium. The resulting
cell suspension was cultured on the poly-L-lysine-coated cover
slips (PLL, Sigma–Aldrich, St. Louis, MO, USA), in a humidified
atmosphere with 5% CO2 at 37◦C, and maintained in basal
medium supplemented with tamoxifen/4-hydroxytamoxifen/
N-desmethyltamoxifen/(E/Z)-N-desmethyl-4-hydroxytamoxifen
(endoxifen)/(E/Z)-N,N-didesmethyl-4-hydroxytamoxifen (nore-
ndoxifen) (Toronto Research Chemicals INC, Canada), in
concentrations ranging from 0.5 ng/ml to 2000 ng/ml. After
3 days of cultivation, the cover slips were used for quantification
of tomato-positive (tomato+) cells.
Cell Quantification
For quantification of tomato+ cells, mice were treated
with 4-hydroxytamoxifen in two doses [0.05 to 40 mg/kg
intraperitoneally (i.p.)] for two consecutive days. Two days
after the second 4-hydroxytamoxifen injection, mice were
deeply anesthetized with pentobarbital (100 mg/kg, i.p.) and
perfused transcardially with 20 ml of saline followed by 20 ml
of cooled 4% paraformaldehyde (PFA), in 0.1 M phosphate
buffer (PB). Brains were dissected out, post-fixed overnight
with PFA, and treated with a sucrose gradient (ranging from 10
to 30%) for cryoprotection. Coronal 30 µm-thick slices were
prepared using a cryostat (Leica CM1850, Leica Microsystems,
Wetzlar, Germany). Cover slips with cell cultures were fixed
for 10 min using 4% PFA in 0.1 M PB. All chemicals were
purchased from Sigma–Aldrich (St. Louis, MO, USA). The brain
slices, along with fixed cover slips were mounted using Aqua
Poly/Mount (Polysciences Inc., Eppelheim, Germany). A Zeiss
510DUO LSM confocal microscope equipped with Ar/HeNe
lasers and 20x objective was used for histo-/cyto-chemical
analyses. For quantification of cultivated cells, at least three
independent cultivations for each concentration of tamoxifen
and its metabolites were used. For quantification of tomato+ cells
in brain slices, 1–3 mice were used for particular concentration
of administrated 4-hydroxytamoxifen.
Liquid Chromatography-Mass
Spectrometry
Sample Preparation
For determination of brain/blood concentration of tamoxifen
and its metabolites, tamoxifen was administered to mice in
one/two/five doses (100/200 mg/kg i.p.) 24 h apart. After 6 h,
2, 4, 6, and 8 days the mice were decapitated, and the brains
were quickly dissected out/blood samples were collected and
frozen at −80◦C until sample processing. In the case of mice
with FCI, tamoxifen was administrated in two doses (200 mg/kg
i.p.) 24 h apart, and 3 days after the second tamoxifen injection,
the FCI was induced, and 1 day after FCI induction, the brains
were isolated. According to (Lien et al., 1991), the brains were
homogenized (1:5, w:v) in ice cold 50 mM Tris-HCl (Sigma–
Aldrich, St. Louis, MO, USA), pH 7.4 using a tissue ruptor
homogeniser (Qiagen, Hilden, Germany). Brain homogenates
were mixed with acetonitrile (1:1, v:v) and precipitated proteins
removed by centrifugation (15 000 g for 6 min). The supernatants
represented extracts for analysis by liquid chromatography
coupled with mass spectrometry (LC-MS). The same procedure
applied to tamoxifen non-treated mice was used to prepare
analyte-free matrix. For each analyzed time-point we used 3–5
mice with the exception of aged mice treated with full dose of
tamoxifen at time-point 2 days. At this time-point we analyzed
two mice and due to high mortality of aged mouse we reduced
the initial tamoxifen dose in the next experiments with aged
mice.
Chemicals and Standard Solutions
Standards of tamoxifen, 4-hydroxytamoxifen, N-desmethyl-
tamoxifen, (E/Z)-N-desmethyl-4-hydroxytamoxifen (endoxifen),
(E/Z)-N,N-didesmethyl-4-hydroxytamoxifen (norendoxifen),
and (Z)-4-hydroxytamoxifen-d5 were purchased from Toronto
Research Chemicals INC (Toronto, ON, Canada). The ratio
of Z and E isomers in N-desmethyl-4-hydroxytamoxifen (48%
of Z isomer) and N,N-didesmethyl-4-hydroxytamoxifen (66%
of Z isomer) was determined by liquid chromatography
under isocratic conditions (35% B) with UV detection
at 245 nm (further conditions are described below in
the LC-MS analysis paragraph). The standards were
dissolved in acetonitrile, at the concentration of 200 µg/ml
and diluted with analyte-free matrix at the required
concentration.
Calibration Curves and Validation
A validated method (Teunissen et al., 2011) for determination
of tamoxifen and its main phase I metabolites was adopted
for analysis of the samples. Four five-point calibration curves
were constructed: (1) From limit of detection (LOD) (0.625
or 1.250 ng/ml) to 10 ng/ml; (2) from 5 to 160 ng/ml;
(3) from 62.5 ng/ml to 1000 ng/ml; and (4) from 1 to
64 µg/ml. Calibration solutions, quality control (QC) samples
and extracts for calibrations (3) and (4) were, prior to analysis
diluted 100x with the analyte-free matrix. The calibration
curves were fitted linearly or quadratically with the residual
values lower than 15% (20% for a limit of quantification –
LOQ – level). QC samples were measured in triplicates
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at the LOQ, low, middle and high concentration levels of
the respective calibration curve. Recovery values of the QC
samples between 85 and 115% (80–120% for LOQ) and relative
standard deviation lower than 5% for all QC samples and all
analytes demonstrated satisfactory accuracy and precision of the
method. LOQ values were determined as follows: 1.25 ng/ml
for 4-hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen;
0.625 ng/ml for tamoxifen, N-desmethyl-tamoxifen, and N,N-
didesmethyl-4-hydroxytamoxifen. LOD values were determined
as 0.313 ng/ml for all analytes.
LC-MS Analysis
(Z)-4-Hydroxytamoxifen-d5 was used as the internal standard
for all determined analytes, at the final concentration of 2.5
(calibrations 1 and 3) or 40 ng/ml (calibrations 2 and 4).
The extracts, calibration or QC samples were centrifuged (13
000 rpm, 5 min) and mixed with the solution of internal
standard in acetonitrile [9:1 (v:v)] or diluted 100x with
analyte-free extract and then mixed with the solution of
internal standard in acetonitrile [9:1, (v:v)]. The samples were
analyzed on an Acquity UPLC system with an LCT premier
XE time-of-flight mass spectrometer (Waters, Milford, MA,
USA) using the liquid chromatography column Acquity UPLC
BEH C18 (50 mm × 2.1 mm I.D., particle size 1.7 µm,
Waters, Milford, MA, USA) and a two-component mobile
phase. The mobile phase A and B consisted of 0.1% formic
acid in water and acetonitrile, respectively. The analyses were
performed under a linear gradient program (min/%B) 0/30,
2/30, 6.5/52.5 followed by a 1 min column clean-up (95%
B) and a 1.5 min equilibration (30% B). The total analysis
time was 9 min. The column temperature was set at 30◦C,
and flow rate at 0.4 ml/min. The mass spectrometer operated
in the V mode, the capillary voltage was set at +2600 V;
cone voltage, +40 V; desolvation gas temperature, 350◦C;
ion source block temperature, 120◦C; cone gas flow, 50 L/h;
desolvation gas flow, 800 L/h; ion guide 1 and 2 RFs, 200
and 300 V, respectively; hexapole RF, 150 V. Ions in the m/z
range 100–1000 were detected using a scan time of 0.15 s
and an inter-scan delay of 0.01 s. The mass accuracy was
kept below 5 ppm using lock spray technology, with leucine
enkephalin as the reference compound (2 ng/µl, 5 µl/min).
The data were processed with MassLynx software using the
QuanLynx application manager (Waters, Milford, MA, USA).
The chromatograms of ions corresponding to [M+H]+ adducts
were extracted with the tolerance window of 0.05 Da, and
smoothed (mean method, two smoothing iterations, width of 2
scans).
Statistics
The results are expressed as the mean± SEM. Statistical analyses
of the differences among groups were performed using one-way
ANOVA for multiple comparisons with Tukey’s post hoc test
and Student’s t-test when appropriate. Values without the error
bars were under the LOD. Values of p < 0.05 were considered
significant, p < 0.01 very significant and p < 0.001 extremely
significant.
RESULTS
In this study, we aimed to clarify the degradation kinetics
of tamoxifen and its metabolites in the mouse brain in the
context of genetic fate-mapping using Cre-loxP systems. Since,
to the best of our knowledge, no work showing how long
tamoxifen and its active metabolites remain in the brain in
effective concentration is available, we wanted to define the
time window allowing complete degradation of tamoxifen and
its metabolites. This is of particular importance regarding
the experiments in which the cell fate is influenced by any
treatment, such as surgery or drug administration. The time
window between tamoxifen administration and the treatment
should be large enough to allow complete degradation of
tamoxifen and its metabolites, otherwise they might promote
recombination in the cells that start to express the Cre
recombinase, as a result of the treatment, which can lead
to data misinterpretation. We first tested the efficacy of
tamoxifen and its metabolites in our Cre-loxP system –
Cspg4/tomato mice – in vitro, and subsequently we determined
the effective brain concentration of the most potent metabolite
4-hydroxytamoxifen, and degradation kinetics of tamoxifen and
its metabolites in vivo.
Biological Activity of Tamoxifen and Its
Metabolites In vitro
Tamoxifen, is extensively metabolized in vivo, in hepatic cells,
predominantly by cytochrome P450 system via two pathways, 4-
hydroxylation and N-demethylation. The majority of tamoxifen
is transformed to N-desmethyltamoxifen, and subsequently to
endoxifen and norendoxifen. The rest is metabolized to 4-
hydroxytamoxifen, which can also be transformed to endoxifen
in the next step (Jordan, 2007) (Figure 1).
To test the ability of tamoxifen and its metabolites to
promote recombination in Cspg4/tomato mice, we isolated
cells from the brains of neonatal Cspg4/tomato mice,
cultivated them with different concentrations of tamoxifen
or its metabolites, and subsequently, quantified the number
of recombined (i.e., tomato+) cells. The highest capability
to promote recombination, possess 4-hydroxytamoxifen
with EC50 of 7.6 ± 2.5 ng/ml (Supplemental Figure
S1B), followed by endoxifen (EC50 = 32.1 ± 1.6 ng/ml),
norendoxifen (EC50 = 224.5 ± 20.4 ng/ml), tamoxifen
(EC50 = 553.4 ± 68.4 ng/ml) and N-desmethyltamoxifen,
which, despite being the main metabolite of tamoxifen, showed
no biological activity within the range of concentrations tested
(Figure 2). These data correspond well with previous studies
and confirm the outstanding efficacy of 4-hydroxytamoxifen
when compared to other tamoxifen metabolites (Table 1)
(Katzenellenbogen et al., 1984; Desta et al., 2004; Jordan, 2007).
Degradation Kinetics of Tamoxifen and
Its Metabolites In vivo
Since the metabolism rate may vary depending on different
gender, strain, age and initial tamoxifen dose, we followed the
fate of administrated tamoxifen in mouse brains in three sets
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FIGURE 1 | Scheme of tamoxifen metabolism. Tamoxifen is metabolized mainly via N-demethylation into N-desmethyltamoxifen, and subsequently endoxifen
and norendoxifen. Minority of tamoxifen is 4-hydroxylated to form 4-hydroxytamoxifen, which can be further transformed to endoxifen. The thickness of the arrows
indicates the major direction of tamoxifen conversion.
FIGURE 2 | Effectivity of tamoxifen and its metabolites in promoting
recombination in vitro. The most potent metabolite of tamoxifen is
4-hydroxytamoxifen with EC = 7.6 ± 2.5 ng/ml, followed by endoxifen
(EC = 32.1 ± 1.6 ng/ml), norendoxifen (EC = 224.5 ± 20.4 ng/ml), tamoxifen
itself (EC = 553.4 ± 68.4 ng/ml) and inactive N-desmethyltamoxifen.
of experiments. In the first set, we assessed the gender-, strain-,
and age-related differences. In the second set of experiments we
evaluated the changes caused by different dosing, and in the
third set we tested the influence of FCI on the concentration of
tamoxifen and its metabolites in the brain.
In the first set of experiments, we used a total dose of
400 mg/kg of tamoxifen, divided into two doses of 200 mg/kg,
applied 24 h apart. Such a dose was selected as an approximate
average of doses used in many studies using Cre-loxP systems
(Leone et al., 2003; Kang et al., 2010, 2013; Li et al., 2010;
De Biase et al., 2011; Komitova et al., 2011; Clarke et al.,
2012; Benner et al., 2013; Robins et al., 2013). We chose
the 2-doses scheme since in our hands use of just one dose
of 200 mg/kg of tamoxifen resulted in lower recombination
rate when compared to two doses (Supplemental Figure S1C).
The brain concentration of tamoxifen and its metabolites
was analyzed 6 h and 2, 4, 6, and 8 days after the second
tamoxifen application. As depicted in Figure 3 the degradation
kinetics of tamoxifen and 4-hydroxytamoxifen were exponential-
like, whereas those of endoxifen, N-desmethyltamoxifen and
norendoxifen were characterized by a plateau phase preceding
the exponential-like phase. This plateau phase is probably caused
by faster production rate of endoxifen, N-desmethyltamoxifen
and norendoxifen compared to their degradation rate as is
shown in Figure 1. All substances were completely metabolized
within 8 days with an exception of N-desmethyltamoxifen.
Noteworthy, the peak brain concentration of tamoxifen, 6 h
after the second application was 36792.0 ± 6891.8 ng/g, which
represents 9.2 ± 1.7% of the total tamoxifen dose applied,
and more importantly, the peak brain concentration of 4-
hydroxytamoxifen was 2098.0 ± 304.5 ng/g, which is only
0.5% of the active metabolite from the total tamoxifen dose.
Although no differences were observed in degradation kinetics
between young adult male and female mice of the same strain,
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TABLE 1 | Comparison of biological activity of tamoxifen and its metabolites determined in this study and in Katzenellenbogen et al. (1984), Desta et al.
(2004), and Jordan (2007).
This study Desta et al., 2004; Jordan, 2007 Katzenellenbogen et al., 1984
Cells isolated from Cspg4/Tom
mouse
Rat uterus/MCF-7 breast cancer
cell line
MCF-7 breast cancer cell line
Affinity for Cre-ERTM (ability to
promote recombination) [%]
Affinity for estrogen
receptor/suppression of cell
growth [%]
Affinity for estrogen
receptor/suppression of cell
growth [%]
Tamoxifen 100 100 100
4-Hydroxytamoxifen ∼7000 ∼3000–10000 ∼12400
Endoxifen ∼1700 ∼3000–10000 —
Norendoxifen ∼250 — —
N-desmethyltamoxifen Ineffective — —
we detected differences in degradation kinetics between mice
of different strains. The degradation kinetics of FVB/NJ mice
is slightly, but significantly, faster than that of the C57BL/6J
mice, which is further documented by a steeper plateau phase
in the degradation kinetics of endoxifen, N-desmethyltamoxifen
and norendoxifen in the case of FVB/NJ mice (Figure 3). The
last, but most striking finding from this set of experiments
is the fact that aged (over 15 months) C57BL/6J mice were
almost unable to degrade all substances within 6 days. In fact,
the majority of old mice died before we could analyze them,
which is the reason for the missing 8 days time-point in our
analysis.
In the second set of experiments, we evaluated the influence
of different doses of tamoxifen, as well as different dosing
schemes on the degradation kinetics of tamoxifen and its
metabolites in young adult C56BL/6J male mice. As a control,
we used the application scheme of 2 × 200 mg/kg (high
dose), the same as in the first experimental set, and then
we tested 2 × 100 mg/kg, (low dose) 24 h apart and
5 × 100 mg/kg 24 h apart in 5 consecutive days. Eventually,
we also tested the dose of 2 × 100 mg/kg in aged (over
15 months) C57BL/6J male mice. As expected, in the case of low
doses of tamoxifen, the degradation kinetics were significantly
faster when compared with that of high doses (Figure 4),
while the recombination rate was preserved (Supplemental
Figure S1C). Surprisingly, although the peak concentrations
of tamoxifen and N-desmethyltamoxifen in the brain were
significantly decreased when the low dose was used, the peak
concentration of 4-hydroxytamoxifen in the brain remained
unchanged, independent of initial tamoxifen dose (Figure 5).
Regarding the aged mice, the lower dose of tamoxifen improved
their survival rate to 100% and allowed them to degrade all
substances within 8 days. The aged mice with the low dose of
tamoxifen, showed the same degradation rate as young adult
mice with the high dose of tamoxifen with exceptions for
N-desmethyltamoxifen in time-point 2 days and endoxifen in
time-point 4 days. Interestingly, the degradation kinetics of
tamoxifen and its metabolites after single 200 mg/kg dose scheme
was comparable with that of low dose; however, the single
dose scheme resulted in lower recombination rate (Supplemental
Figure S2)
Finally, we tested the impact of disruption of the blood-brain
barrier caused by FCI on the concentration of tamoxifen and its
metabolites. For this purpose, we performed FCI in young adult
mice 3 days after the last tamoxifen treatment (2 × 200 mg/kg).
The brain concentration of tamoxifen and its metabolites were
analyzed 24 h after FCI induction, which corresponds to day 4 in
control animals. Interestingly, no changes in the concentration
of all substances were detected when compared to uninjured
animals (Figure 6).
Taken together, tamoxifen metabolism in the brain depends
on mouse strain, age of the animal and initial tamoxifen
dose. Our results show that a low dose of tamoxifen results
in sufficient 4-hydroxytamoxifen concentration in the brain,
which promotes maximal recombination, and moreover, it is
not lethal for aged mice with presumed tamoxifen metabolism
limitations. Interestingly, although concentrations of tamoxifen
and its metabolites in the brain varied significantly based on
the age and dose and persisted in the brain for a long time,
the blood concentrations were not dose- or age-dependent,
with exception for tamoxifen 6 h after its administration
(Supplemental Figure S3).
Minimal Effective Concentration of
4-Hydroxytamoxifen in the Brain In vivo
Since the effective concentration of tamoxifen necessary to
promote recombination in vivo, could hardly be determined
due to its ongoing metabolism to form much more effective 4-
hydroxytamoxifen, we determined the minimal effective brain
concentration of 4-hydroxytamoxifen itself. 4-hydroxytamoxifen
is metabolized to endoxifen, which is less effective than
4-hydroxytamoxifen, and therefore its influence on the 4-
hydroxytamoxifen efficacy could be neglected.
For this purpose, we treated Cspg4/tomato mice with a
different concentration of 4-hydroxytamoxifen, and quantified
the number of recombined tomato+ cells in fixed brain slices
(Supplemental Figure S1D). From such analysis we obtained
a relationship between the number of tomato+ cells, and
4-hydroxytamoxifen concentration, which was fitted well by
a sigmoidal curve, allowing us to calculate the spontaneous
recombination rate, and minimal concentration of administrated
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FIGURE 3 | Gender-, strain- and age-dependent differences in degradation of tamoxifen and its metabolites. Degradation of tamoxifen and its metabolites
is significantly affected by age and strain of the mice. Significances are expressed above the x-axis by an asterisk in the color of the respective group relative to the
male group (green line). Values of p < 0.05 were considered significant (∗), p < 0.01 very significant (∗∗).
4-hydroxytamoxifen necessary to promote additional
recombination above the spontaneous level (Figure 7A). The
theoretical spontaneous recombination in Cspg4/tomato mice,
calculated from the fitted curve, occurs in 5.0 ± 1.3% of cells
from the maximal recombination rate observed, which correlates
well with the spontaneous recombination rate obtained from
non-treated animals (Supplemental Figure S1D). By subtracting
the spontaneous recombination rate from the percentage of
tomato+ cells, it enabled us to determine that the minimal
effective concentration of administrated 4-hydroxytamoxifen
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FIGURE 4 | Dose-dependent differences in degradation of tamoxifen and its metabolites in the mouse brains. Degradation of tamoxifen and its
metabolites is significantly affected by initial tamoxifen dose. Significances are expressed above the x-axis by an asterisk in the color of the respective group relative
to 2 × 200 mg/kg group (green line). Values of p < 0.05 were considered significant (∗), p < 0.01 very significant (∗∗) and p < 0.001 extremely significant (∗∗∗).
capable of promoting recombination above the spontaneous
level, is 4.5± 1.3 mg/kg (Figure 7A).
Next, we determined the peak concentration of 4-
hydroxytamoxifen in the brain after administration of
5 and 20 mg/kg of 4-hydroxytamoxifen, using LC-MS in
order to reveal the relationship between 4-hydroxytamoxifen
concentration in the brain and concentration of administrated
4-hydroxytamoxifen. From the resulting values (47.5 ± 6.3 ng/g
and 165.4 ± 22.7 ng/g for 5 and 20 mg/kg of administrated 4-
hydroxytamoxifen, respectively) we obtained a linear relationship
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FIGURE 5 | Difference in concentration of 4-hydroxytamoxifen at day
0, after administration of 2 × 200 or 2 × 100 mg/kg of tamoxifen. No
difference in concentration of 4-hydroxytamoxifen, unlike those of tamoxifen
and N-desmethyltamoxifen, suggests that the pathway toward the most
potent metabolite is saturated already, when 2 × 100 mg/kg of tamoxifen i.p.
was administrated. Values of p < 0.05 were considered significant (∗).
characterized with the equation y = 8.4x (Figure 7B). By
substituting the x-value with the minimal effective concentration
of administrated 4-hydroxytamoxifen, 4.5 ± 1.3 mg/kg,
we calculated that the minimal effective concentration of
4-hydroxytamoxifen in the brain, which is necessary to promote
recombination in vivo, was 38.0± 22.0 ng/g (Figure 7B).
In conclusion, the concentration of 4-hydroxytamoxifen in the
brain decreases to the ineffective level within 6 days in the case of
high doses, and within 4 days in the case of low doses in young
adult mice (Figure 4).
DISCUSSION
To prevent undesirable recombination caused by residual
concentrations of tamoxifen and its metabolites in the mouse
brain, it is important to know the time window that allows
their complete degradation. Moreover, it is also essential to
obtain the highest possible recombination rate with minimal
animal mortality in Cre-loxP systems, which should lead to
cell-type specific gene knockout. Therefore, in this study we
FIGURE 6 | Influence of blood-brain barrier disruption on brain
concentration of tamoxifen and its metabolites. Disruption of the
blood-brain barrier by the middle cerebral artery occlusion, causes no
changes in the ipsilateral hemisphere concentration of any tamoxifen
metabolites.
identified the minimal effective concentration of the most potent
tamoxifen metabolite4-hydroxytamoxifen, which can promote
recombination in the brains of C56BL/J mice. After determining
the degradation kinetics of tamoxifen and its metabolites, we
disclosed that all metabolites are degraded within 8 days when
the dose of 2 × 200 mg/kg of tamoxifen is used. Furthermore,
we revealed that the degradation time depends strongly on the
initial dose of tamoxifen, since 6 days are sufficient for complete
degradation of 2 × 100 mg/kg tamoxifen administration. Mouse
age also plays an important role, because aged mice showed a high
mortality rate after 2 × 200 mg/kg of tamoxifen administration,
and they were unable to degrade tamoxifen or its metabolites
within 6 days. Therefore, we conclude that a low dose of
tamoxifen is sufficient to promote full recombination, and has
minimal toxicity even in aged mice. In addition, we showed that
disruption of the blood-brain barrier by FCI has no impact on the
brain concentrations of tamoxifen and its metabolites.
Effectivity of Tamoxifen and Its
Metabolites to Promote Recombination
So far, the potency of tamoxifen and its metabolites was assessed
in relation to their anti-estrogenic effects, primarily in tumor cell
lines (Katzenellenbogen et al., 1984; Desta et al., 2004; Lim et al.,
2005; Jordan, 2007). Here we tested the affinity of tamoxifen and
its metabolites to cre-ERTM (cre-Esr1∗) (Hayashi and McMahon,
2002), which corresponds to their ability to trigger recombination
in our Cre-loxP system. Similarly to their anti-estrogenic effects
(Katzenellenbogen et al., 1984; Desta et al., 2004; Lim et al.,
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FIGURE 7 | Minimal effective 4-hydroxytamoxifen concentration in
mouse brains. (A) Spontaneous recombination takes place in 3% of cells
(indicated by the red line), relative to the maximal recombination rate. An
additional recombination over the spontaneous level was caused by the
administration of 4-hydroxytamoxifen in concentration exceeding
4.5 ± 1.3 mg/kg (indicated by the red arrow), (B) which corresponds to
4-hydroxytamoxifen concentration of 38.0 ± 22.0 ng/g in the brain.
2005; Jordan, 2007), the highest potency to bind cre-ERTM and
thus to promote recombination, exhibited 4-hydroxytamoxifen.
Tamoxifen and endoxifen showed 55-times and 4-times lower
potency to bind cre-ERTM than 4-hydroxytamoxifen, respectively
(Figure 1). Although it was shown that N-desmethyltamoxifen
displays similar biological activity as tamoxifen regarding their
anti-estrogenic effects (Desta et al., 2004; Lim et al., 2005; Jordan,
2007), we found that N-desmethyltamoxifen is ineffective in its
ability to bind and to activate cre-ERTM. This discrepancy is
probably caused by structural differences between the estrogen
receptor and ERTM, which is a mutant form of the ligand-binding
domain of the estrogen receptor (Hayashi and McMahon, 2002).
Norendoxifen, so far studied mostly for its aromatase-inhibiting
properties (Lu et al., 2012), showed twice higher potency
compared to tamoxifen.
Degradation Period of Tamoxifen and Its
Metabolites in the Mouse Brain
We assessed the i.p. administration of tamoxifen since the
other possibilities of tamoxifen administration are not so
reliable. Administration via drinking water is limited by
the solubility of tamoxifen in the water and a long period
of administration necessary to achieve the satisfactory
recombination. The oral gavage seems to be more stressful
for animals and moreover it is more time-consuming than i.p.
administration. The i.p. administration is highly reproducible
and easy to perform. According to Lien et al. (1991), the
peak concentration of tamoxifen and its metabolites in the
brain was measured 6 h after the last tamoxifen injection.
Tamoxifen and N-desmethyltamoxifen showed the highest brain
accumulation after two intraperitoneal tamoxifen applications.
4-hydroxytamoxifen showed 20-fold lower concentration
in the brain, while endoxifen and norendoxifen did not
even reach 1% of tamoxifen and N-desmethyltamoxifen
concentration levels. This observation is partly in contrast
with the work of Lien et al. (1991) and Iusuf et al. (2011), who
found that N-desmethyltamoxifen and 4-hydroxytamoxifen
brain concentration is twice lower compared to tamoxifen
concentration in the brain. Such discrepancies were probably
caused by different types of tamoxifen administration. While
we used two intraperitoneal doses, Lien et al. (1991) and (Iusuf
et al. (2011) administrated tamoxifen orally in one, three or
fourteen doses, thus incorporating the gastro-intestinal tract
into tamoxifen biotransformation. Moreover, Lien et al. (1991)
used rats instead of mice in their work. On the other hand,
consistently with Lien et al. (1991) and (Iusuf et al., 2011) we
detected only traces of endoxifen, which is caused by its poor
ability to cross the blood-brain barrier (Iusuf et al., 2011).
The complete degradation of tamoxifen and its metabolites,
after the dose of 2 × 200 mg/kg, occurred within 8 days
in young adult C57BL/6J mice with an exception for
N-desmethyltamoxifen, which did not reach undetectable
brain concentration within 8 days. Although we did not
detect any differences in the degradation of tamoxifen and
its metabolites between males and females, we did so between
different mouse strains (Figure 3). FVB/NJ mice had significantly
lower concentration of tamoxifen and its metabolites in the brain
in several time-points when compared to C57BL/6J mice. These
results point to strain-dependent differences in the metabolic
processes, which were documented previously by Berglund et al.
(2008) and Vaillant et al. (2014). Besides the strain-dependent
differences, we also observed a major age-related alteration in
the degradation of tamoxifen and its metabolites. In agreement
with observations that metabolic rate decreases with aging
(Houtkooper et al., 2011), aged mice were unable to degrade
the tamoxifen and its metabolites within 6 days (Figure 3). This
often led to the death of aged animals prior to the final time-point
of our experiments.
We also tested the ability of mice to degrade tamoxifen
and its metabolites after the administration of a lower dose
(2× 100 mg/kg of tamoxifen). Obviously, lower tamoxifen doses
led to significantly faster degradation of all tamoxifen metabolites
within 6 days (Figure 4). Interestingly, the peak concentration
of 4-hydroxytamoxifen in the brain reached the same level
independently of the initial tamoxifen dose (Figure 4). Given
that tamoxifen and N-desmethyltamoxifen peak concentrations
in the brain were significantly lower when a low dose of tamoxifen
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was used, we hypothesize that the mechanisms responsible for
transformation of tamoxifen into 4-hydroxytamoxifen in the
brain are fully saturated already, when the dose of 2× 100 mg/kg
is used. When such a phenomenon is taken into account, using
tamoxifen in the total dose higher than 200 mg/kg is unnecessary,
since it might only lead to higher metabolic stress and does
not increase the recombination rate. A lower dose of tamoxifen
improved the survival rate of aged mice; however, their metabolic
deficits were still evident.
Permanent MCAo resulting in FCI also leads to disruption
of the blood brain barrier, and over-perfusion of the infarcted
site (Yan et al., 2015). Hence, we expected that FCI should affect
concentration of tamoxifen and its metabolites in the brain.
Since we detected no changes in the brain concentration of any
tamoxifen metabolites after FCI, we conclude that this type of
injury has no impact on tamoxifen metabolism. The subsequent
analyzes showed that the blood concentrations of tamoxifen
and its metabolites at day 4 were very low and therefore the
disrupted blood brain barrier and over-perfusion did not change
the concentrations in the brain tissue.
Implications of Tamoxifen Metabolism in
the Brain
The knowledge of degradation kinetics of tamoxifen and its
active metabolites in the mouse brain is of big importance,
especially concerning genetic fate-mapping using the tamoxifen
inducible cre-loxP system. It is important to use the precise
amount of administrated tamoxifen, which causes a sufficient
recombination rate, and simultaneously, to avoid excessive
metabolic stress of animals. Furthermore, the proper time
window for allowing the complete degradation of active
tamoxifen metabolites has to be applied in order to prevent
possible data misinterpretation (labeling of desired cells is
triggered by the expression of cell-type specific marker under
physiological condition. Many of these cell-type specific markers
become widely expressed also in other cell types after pathologic
stages, treatments, aging etc. and therefore the presence of
tamoxifen and its metabolites residues can cause recombination
in non-traced cell types). In addition, the animals age has to
be taken into account during experiment design, since the aged
animals posses some limits in tamoxifen and its metabolites
degradation, and therefore require specific treatment. Moreover,
a wide use of tamoxifen in human medicine could bring other
implications, in which the age of patients and application scheme
should be taken into account.
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